OBJECTIVE:To study the expression of Tie2 and Ang2 in non-small cell lung cancer ( NSCLC) and its clinical significance.METHODS:Immunohistochemistry was used to detect the expression of Tie2 and Ang2 in 50 cases of non-small cell lung cancer(28 cases of adenocarcinoma, and 22 cases squamous cell carcinoma) tissues.RESULTS:The positive expression rates of Tie2 and Ang2 in NSCLC tissues were 52.0%(26/50) and 66.0%(33/50) respectively, as compared with 67.9%(19/28) and 82.1%(23/28) respectively in adenocarcinoma tissues, and all were significantly higher than in squamous cell carcinoma [ 31.8%( 7/22 ) and 45.5%( 10/22 ) ] ( P0.05 ); however, the positive expression of Ang2 was was significantly associated tumor stage/grade, gender and smoking index ( P >0.05 ) . CONCLUSIONS:Tie2 and Ang2 are closely assoicated with the occurrence and development of non-small cell lung cancer, thus the Ang/Tie-2 inhibitors might be used as the novel targeted drugs for non-small cell lung cancer.%目的：探讨促血管生成素2（Ang-2）及其受体Tie-2在非小细胞肺癌组织中的表达及意义。方法：采用免疫组化法分析Tie-2、Ang-2在50例非小细胞肺癌患者（其中腺癌28例，鳞癌22例）组织中的表达。结果：Tie-2、Ang-2在非小细胞肺癌组织中的阳性率分别为52.0％（26／50）、66.0％（33／50）；Tie-2、Ang-2在腺癌组织中阳性率分别为67.9％（19／28）、82.1％（23／28），均明显高于其在鳞癌组织中的阳性率[31.8％（7／22）、45.5％（10／22）]，差异有统计学意义（P＜0.05）。 Tie-2的阳性表达与患者性别、吸烟指数、肿瘤分期分级无关（P＞0.05）；而Ang-2的阳性表达与非小细胞肺癌的分期、分级和患者性别、吸烟指数显著相关（P＜0.05）。结论：Tie-2、Ang-2与非小细胞肺癌的发生、发展关系密切，Ang／Tie-2抑制剂可能成为治疗非小细胞肺癌的新型靶向药物。
展开▼
